A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of ...
Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...
According to the World Health Organization (WHO), lenacapavir offers a highly effective, long-acting alternative to daily ...
Lenacapavir has the potential to end the HIV epidemic, researchers say. The Trump administration says backing this kind of ...
allAfrica.com on MSN
New twice-a-year anti-HIV jab costs as much as daily prevention pill, set to launch by 2027
Two Indian generic drugmakers – Hetero and Dr Reddy’s – will be funded by the Gates Foundation and Unitaid, respectively, to ...
This antiretroviral has shown unprecedented results in HIV prevention, requiring only two injections per year. Its ...
Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...
MedPage Today on MSN
CDC Backs Twice-Yearly Injectable for HIV Prevention
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...
The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Uganda is among the 10 high-burden countries selected to benefit through the US President’s Emergency Plan for Aids Relief ...
Discover how lenacapavir, a revolutionary HIV prevention tool, will be available for just $40 annually to 120 low- and middle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback